<?xml version='1.0' encoding='utf-8'?>
<document id="23921574"><sentence text="Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC)."><entity charOffset="79-91" id="DDI-PubMed.23921574.s1.e0" text="bicalutamide" /></sentence><sentence text="Recent data indicate that there is a significant cross-talk between the PI3K/Akt/mTOR and androgen receptor signaling pathways"><entity charOffset="90-98" id="DDI-PubMed.23921574.s2.e0" text="androgen" /></sentence><sentence text=" We evaluated safety and tolerability as well as potential drug-drug interaction of ridaforolimus, a mammalian target of rapamycin (mTOR) inhibitor, when combined with the androgen receptor inhibitor bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer"><entity charOffset="121-130" id="DDI-PubMed.23921574.s3.e0" text="rapamycin" /><entity charOffset="172-180" id="DDI-PubMed.23921574.s3.e1" text="androgen" /><entity charOffset="200-212" id="DDI-PubMed.23921574.s3.e2" text="bicalutamide" /><pair ddi="false" e1="DDI-PubMed.23921574.s3.e0" e2="DDI-PubMed.23921574.s3.e0" /><pair ddi="false" e1="DDI-PubMed.23921574.s3.e0" e2="DDI-PubMed.23921574.s3.e1" /><pair ddi="false" e1="DDI-PubMed.23921574.s3.e0" e2="DDI-PubMed.23921574.s3.e2" /><pair ddi="false" e1="DDI-PubMed.23921574.s3.e1" e2="DDI-PubMed.23921574.s3.e1" /><pair ddi="false" e1="DDI-PubMed.23921574.s3.e1" e2="DDI-PubMed.23921574.s3.e2" /></sentence><sentence text="" /><sentence text="Patients were treated with the combination of ridaforolimus 30 mg/day for 5 consecutive days each week and bicalutamide 50 mg/day"><entity charOffset="107-119" id="DDI-PubMed.23921574.s5.e0" text="bicalutamide" /></sentence><sentence text=" Ridaforolimus pharmacokinetics was assessed with and without bicalutamide"><entity charOffset="62-74" id="DDI-PubMed.23921574.s6.e0" text="bicalutamide" /></sentence><sentence text="" /><sentence text="Twelve patients were enrolled including 1 screen failure" /><sentence text=" Dose reductions were required in 7 patients" /><sentence text=" Three of the 11 patients experienced a dose-limited toxicity, 1 with Grade 3 hyperglycemia and 2 with Grade 2 stomatitis leading to &lt;75 % of planned ridaforolimus dose during the first 35 days of study treatment" /><sentence text=" The pharmacokinetic results showed no differences in exposures to ridaforolimus with and without concomitant bicalutamide administration"><entity charOffset="110-122" id="DDI-PubMed.23921574.s11.e0" text="bicalutamide" /></sentence><sentence text="" /><sentence text="Although there was no evidence of a clinically relevant pharmacological drug-drug interaction, the occurrence of dose-limiting toxicities in 3 of 11 evaluable patients at a reduced dose of ridaforolimus of 30 mg/day suggests that this combination may not be well suited for asymptomatic or minimally symptomatic prostate cancer patients" /><sentence text="" /></document>